Publications

Articles

Grit Andersen MD, Grégory Meiffren PhD, Susanne Famulla PhD, Tim Heise MD, Aymeric Ranson MSc, Cyril Seroussi MSc, Rosy Eloy MD, Martin Gaudier PhD, Richard Charvet PhD, You‐Ping Chan PhD, Olivier Soula PhD, J. Hans DeVries MD.
« ADO09, a co‐formulation of the amylin analogue pramlintide and the insulin analogue A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes »
Diabetes, Obesity and Metabolism, Volume 21, Issue 7, 03 March 2020. [Epub ahead of print]
Grégory Meiffren PhD, Theresa Herbrand MD, Ernestos Anastassiadis MD, Oliver Klein MD, J. Hans DeVries MD, Tim Heise MD, Bertrand Alluis PhD, Claire Mégret PhD, Martin Gaudier PhD, Olivier Soula PhD, Leona Plum‐Mörschel MD
“Better glycemic control with BioChaperone® Combo (BC Combo) than with insulin lispro Mix25 (LMix) or separate glargine & lispro (G+L) administrations after a test meal in subjects with type 2 diabetes (T2DM)” Journal: Diabetes, Obesity and Metabolism, July 2019
Andersen G, Meiffren G, Lamers D, DeVries JH, Ranson A, Seroussi C, Alluis B, Gaudier M, Soula O, Heise T. “Ultra-rapid BioChaperone® Lispro improves postprandial blood glucose excursions vs insulin lispro in a 14-day crossover treatment study in people with type 1 diabetes.” Diabetes Obes Metab. 2018 Nov;20(11):2627-2632
Heise T, Meiffren G, Alluis B, Seroussi C, Ranson A, Arrubla J, Correia J, Gaudier M, Soula O, Soula R, DeVries JH, Klein O, Bode BW. “Pharmacodynamic and pharmacokinetic properties of BioChaperone® Lispro vs faster aspart and insulin aspart in patients with type 1 diabetes on continuous subcutaneous insulin infusion. A randomized euglycemic clamp study.” Diabetes Obes Metab. 2018 Dec 18. [Epub ahead of print]

Présentations orales

« ADO09, a co-formulation of ramlintide and insulin A21G improves postprandial glucose (PPG) versus insulin Aspart  in type 1 diabetes »,(Oral Presentation), Dr.  Grégory Meiffren, June 2, 2021, ATTD, Virtual event.
« 197-OR – ADO09, a Coformulation of Insulin A21G and Pramlintide (Pram),
Improves Blood Glucose Control and Reduces Body Weight in Subjects with T1D », (Oral Presentation), presented by Dr. Grégory Meiffren, June 27, 2021, ADA virtual event.
« ADO09, une co-formulation de l’analogue d’amyline pramlintide et de l’analogue d’insuline humaine A21G, réduit la glycémie post-prandiale en comparaison à l’insuline lispro chez le diabétique de type 1 », Orateur : Dr.  Grégory Meiffren, 10 Septembre, SFD, Congrès virtuel.
ADO09, a Coformulation of Pramlintide (PRAM) and Insulin A21G, Improves Postprandial Glucose vs. Novolog in Type 1 Diabetes (T1D) (Poster # 2020-LB-7039-Diabetes), presented by Dr. Gregory Meiffren, June 12-16, 2020, ADA virtual experience.
“BioChaperone® Technology Enables The Development Of Pramlintide-Prandial Insulin Combinations”, (Oral Presentation session 4)”, (Oral Presentation), presented by Dr. Grégory Meiffren, February 23, 2019, ATTD, Berlin (Germany)
“The Ultra-Rapid Insulin BioChaperone® Lispro Bolused By Insulin Pump Shows Favourable Pharmacodynamics And Pharmacokinetics vs. Faster Aspart and Insulin Aspart”, (Oral Presentation), presented by Dr. Grégory Meiffren, February 23, 2019, ATTD, Berlin (Germany)
“Comparaison des profils pharmacocinétiques et de pharmacodynamie de l’insuline ultra rapide BioChaperone® Lispro avec les formulations Fiasp® et Novorapid® de l’insuline asparte administrées par pompes à insuline”, (Oral Presentation), presented by Dr. Grégory Meiffren, March 27, 2019, Annual Congress of the Francophone of the Diabetes Society, Marseille (France)
“Biochaperone Pramlintide Insulin (BCPramIns), A New Co-formulation Of Pramlintide (pram) And Human Insulin (ins), Improves Post-prandial Blood Glucose (BG) Versus Both Separate Injections Of Pram+Ins And Insulin Lispro (lis) in Subjects With T1D”, (Oral Presentation), presented by Dr. Grégory Meiffren, June 9th, 2019, ADA, San Francisco (USA)
“BioChaperone® Lispro, an Ultra-Rapid Insulin Lispro Formulation improves post-prandial Blood Glucose Control in a 14-day multiple daily insulin injection study in Subjects with T1DM”, (Oral Presentation ATTD8-0099), presented by Dr. Grégory Meiffren, February 14-17, 2018, ATTD, Vienna (Austria)
“The ultra-rapid insulin BioChaperone® Lispro shows favourable pharmacodynamics and pharmacokinetics compared to faster insulin aspart and insulin aspart in insulin pumps” (Oral Presentation 57), presented by Dr. Grégory Meiffren, 54th Annual Meeting of the European Association for the Study of Diabetes, 1-5 October 2018, Berlin (Germany)
“BioChaperone® Technology Enables the Development of Pramlintide-Prandial Insulin Combinations” (Oral Presentation 349), presented by Dr. Grégory Meiffren, 78th Scientific Sessions of the American Diabetes Association, 22-26 June 2018, Orlando, FL (USA)
“BioChaperone® Glucagon (BCG), a Stable Ready-to-use Liquid Glucagon Formulation, is Well Tolerated and quickly Restores Euglycemia after Insulin-induced Hypoglycemia” (Oral Presentation 305), presented by Dr. Grégory Meiffren, 78th Scientific Sessions of the American Diabetes Association, 22-26 June 2018, Orlando, FL (USA)
“BioChaperone® Lispro, an Ultra-Rapid Insulin Lispro Formulation improves post-prandial Blood Glucose Control in a 14-day multiple daily insulin injection study in Subjects with T2DM”, (Oral Presentation ATTD8-0097), presented by Dr. Grégory Meiffren, February 14-17, 2018, ATTD, Vienna (Austria)
“Ultra-Rapid BioChaperone® Lispro ameliorates postprandial blood glucose (PPG) control compared to Humalog in subjects with type 1 diabetes mellitus”, presented by Dr. Tim Heise, DDG, 2017
“Ultra-Rapid BioChaperone® Lispro Ameliorates Postprandial Blood Glucose (PPG) Control Compared with Humalog® in Subjects with Type 1 Diabetes Mellitus” (Oral Presentation 07), presented by Dr. Tim Heise, 52nd European Association for the Study of Diabetes (EASD) Annual Meeting, 12–16 September 2016, Munich (Germany)
“BioChaperone® Combo, a co-formulation of lispro and glargine, demonstrates both prandial and basal insulin time-action profiles in a single injection in type 2 diabetes” (Oral Presentation 08), presented by Dr. S. Bruce, 52nd European Association for the Study of Diabetes (EASD) Annual Meeting, 12–16 September 2016, Munich (Germany)
“BioChaperone® Combo (BC Combo) Improves Postprandial Glycemia vs. Humalog® Mix 75/25™ (HMx) in People with Type 1 Diabetes Mellitus (T1DM)” (Oral presentation 295-OR), presented by Dr. Steven V. Edelman, 76th Scientific Sessions American Diabetes Association 11-13 June 2016, New Orleans, LO (USA)
“Ultra-Rapid BioChaperone® Lispro Ameliorates Postprandial Blood Glucose (PPG) Control Compared with Humalog in Subjects with Type 1 Diabetes Mellitus” (Oral presentation 294-OR), presented by Dr. Grit Anderen, 76th Scientific Sessions American Diabetes Association 10-14 June 2016, New Orleans, LO (USA)

Posters et abstracts

ADO09, a Coformulation of Pramlintide (PRAM) and Insulin A21G, Improves Postprandial Glucose vs. Novolog in Type 1 Diabetes (T1D) (Poster # 2020-LB-7039-Diabetes), presented by Dr. Gregory Meiffren, June 12-16, 2020, ADA virtual experience.
“BioChaperone® Combo, A Co-Formulation Of Lispro And Glargine, Improves Postprandial Glucose Control Compared To Lispromix25 Or Lispro And Glargine Injections In Type 2 Diabetes Subjects” (EPO2 E-Poster Viewing), presented by Dr. Grégory Meiffren, February 21, 2019, ATTD, Berlin (Germany)
“BioChaperone® Glucagon, A Stable Ready-To-Use Liquid Glucagon Formulation Enabled By Biochaperone Technology, Is Well Tolerated And Quickly Restores Euglycemia After Insulin-Induced Hypoglycemia” (E-Poster Discussion 05), presented by Mr. Aymeric Ranson, February 22, 2019, ATTD, Berlin (Germany)
“BioChaperone Combo, une combinaison fixe d’insuline lispro et d’insuline glargine, améliore les profils de glycémie postprandiale par rapport à un premix d’insuline lispro et les administrations séparées d’insuline lispro et d’insuline glargine dans une étude de phase 1 chez des sujets diabétiques de type 2” (Poster), Author Dr. Claire Mégret, March 26, 2019, Annual Congress of the Francophone of the Diabetes Society, Marseille (France)
“BioChaperone Glucagon, une formulation de glucagon liquide, stable, prête à l’emploi, est bien tolérée et rétablit rapidement la normoglycemie après une hypoglycémie provoquée par infusion d’insuline” (Poster), Author Mr. Aymeric Ranson, March 26, 2019, Annual Congress of the Francophone of the Diabetes Society, Marseille (France)
“BioChaperone Glucagon Exenatide (BC Glu Exe), a Stable Combination of Glucagon (Glu) and Exenatide (Exe) Achieved Larger Body Weight (BW) Loss than Exe Alone in DIO Mice” (Poster), Author Dr. Martin Gaudier, June 10, 2019, ADA, San Francisco (USA)
“BioChaperone® technology enables the development of pramlintide-prandial insulin combinations” (Poster 811), presented by Dr. Remi Soula, 54th Annual Meeting of the European Association for the Study of Diabetes, 1-5 October 2018, Berlin (Germany)
“Better Postprandial Glucose (PPG) Control with BioChaperone® Combo (BC Combo) than with Lispro Mix25 (LMx) or separate Glargine & Lispro (G+L) Administration in Subjects with Type 2 Diabetes (T2DM)” (Poster 1001), presented by Dr. T. Herbrand, 54th Annual Meeting of the European Association for the Study of Diabetes, 1-5 October 2018, Berlin (Germany)
“Pooled analysis of clinical trials investigating the pharmacokinetics (PK) of ultra-rapid insulin BioChaperone® Lispro vs lispro in subjects with type 1 and type 2 diabetes” (Poster 815), presented by Dr. Tim Heise, 54th Annual Meeting of the European Association for the Study of Diabetes, 1-5 October 2018, Berlin (Germany)
“BioChaperone® 222, the new excipient enabling the ultra-rapid BioChaperone® Lispro formulation, is completely absorbed and rapidly excreted after subcutaneous injection” (Poster 816), presented by Dr. Olivier Soula, 54th Annual Meeting of the European Association for the Study of Diabetes, 1-5 October 2018, Berlin (Germany)
“Better Postprandial Glucose (PPG) Control with BioChaperone® Combo (BC Combo) than with Lispro Mix25 (LMx) or separate Glargine & Lispro (G+L) Administration in Subjects with Type 2 Diabetes (T2DM)” (Poster 1001), presented by Dr. Tim Heise, 78th Scientific Sessions of the American Diabetes Association, 22-26 June 2018, Orlando, FL (USA)
“BioChaperone® 222 (BC222), the New Excipient Enabling the Ultra-rapid BioChaperone Lispro (BCLIS) Formulation, Is Completely Absorbed and Rapidly Excreted after Subcutaneous (s.c.) Injection” (Poster 1024), presented by Dr. Grégory Meiffren, 78th Scientific Sessions of the American Diabetes Association, 22-26 June 2018, Orlando, FL (USA)
“Pooled Analysis of Clinical Trials Investigating the Pharmacokinetics (PK) of Ultra-Rapid Insulin BioChaperone® Lispro (BCLIS) versus Lispro (LIS) in Subjects with Type 1 (T1D) and Type 2 (T2D) Diabetes” (Poster 998), presented by Dr. Tim Heise, 78th Scientific Sessions of the American Diabetes Association, 22-26 June 2018, Orlando, FL (USA)
“The Ultra-Rapid Insulin (URI) BioChaperone® Lispro (BCLIS) shows Favorable Pharmacodynamics (PD) and Pharmacokinetics (PK) vs Faster Aspart (FIA) and Insulin Aspart (ASP) in Insulin Pumps (CSII)” (Poster 1035), presented by Dr. Bruce W. Bode, 78th Scientific Sessions of the American Diabetes Association, 22-26 June 2018, Orlando, FL (USA)
“BioChaperone® Lispro, une formulation ultra-rapide d’insuline lispro, améliore le contrôle glycémique post-prandial de sujets diabétiques de type 1 traités par de multiples injections quotidiennes d’insuline pendant 14 jours.” (Abstract CAD-19), presented by Dr. Grégory Meiffren, 2018, Société Francophone du Diabète (France)
“BioChaperone® Lispro, une formulation ultra-rapide d’insuline lispro, améliore le contrôle glycémique post-prandial de sujets diabétiques de type 2 traités par de multiples injections quotidiennes d’insuline pendant 14 jours.” (Abstract CAD-19), presented by Dr. Grégory Meiffren, 2018, Société Francophone du Diabète (France)
“Ultra-rapid BioChaperone® Lispro ameliorates postprandial blood glucose (PPG) control compared to Humalog in subjects with type 1 diabetes mellitus” (Poster PI005), presented by Dr G. Anderson, American Society for Clinical Pharmacology & Therapeutics (ASCPT)
“BioChaperone® Lispro, an Ultra-Rapid Insulin Lispro Formulation improves post-prandial Blood Glucose Control in a 14-day multiple daily insulin injection study in Subjects with T2DM”, (Oral Presentation ATTD8-0097), presented by Dr. Tim Heise, February 14-17, 2018, ATTD, Vienna (Austria)
“Ultra-rapid BioChaperone® Lispro improves post-prandial blood glucose excursions versus insulin lispro in a 14-day treatment study in subjects with type 1 diabetes” (Poster 686), presented by Dr. Grégory Meiffren, 53rd Annual Meeting of the European Association for the Study of Diabetes, 11-15 September 2017, Lisbon (Portugal)
“BioChaperone® technology enables the development of pramlintide-prandial insulin combinations” (Poster 811), presented by Dr. Rémi Soula, 53rd Annual Meeting of the European Association for the Study of Diabetes, 11-15 September 2017, Lisbon (Portugal)
“Ultra-rapid BioChaperone® Lispro (BCLIS) Improves Postprandial Blood Glucose (PPG) Excursions vs. Insulin Lispro (LIS) in a 14-Day Treatment Study in Subjects with Type 1 Diabetes (T1DM)” (Poster 964) presented by Dr. Tim Heise, 77th Scientific Sessions of the American Diabetes Association, 9-13 June 2017 in San Diego, CA (USA)
“Ultra-rapid BioChaperone® Lispro (BCLIS) Improves Postprandial Blood Glucose (PPG) Control vs. Insulin Lispro (LIS) in a14-Day Treatment Study in Subjects with Type 2 Diabetes (T2DM)” (Poster 994) presented by Dr. Tim Heise, 77th Scientific Sessions of the American Diabetes Association, 9-13 June 2017 in San Diego, CA (USA)
“Proportional Dose-Exposure Relationship of Ultra-rapid BioChaperone® Lispro (BCLIS) in Healthy Japanese Subjects” (Poster 996), presented by Dr. Grégory Meiffren, 77th Scientific Sessions of the American Diabetes Association, 9-13 June 2017 in San Diego, CA (USA)
“Preclinical Efficacy of a Stable Aqueous Formulation of Human Glucagon with BioChaperone® Technology (BC GLU)” (Poster 1150), presented by Dr Grégory Meiffren, 77th Scientific Sessions of the American Diabetes Association, 9-13 June 2017 in San Diego, CA (USA)
“Profil pharmacodynamique de BioChaperone® Combo, une co-formulation liquide des insulines lispro et glargine, chez des sujets diabétiques de type 2” (Abstract CAD-19), presented by Dr. Martin Gaudier, 2017, Société Francophone du Diabète (France)
“L’insuline ultra-rapide BioChaperone® Lispro améliore le contrôle glycémique postprandial par rapport à Humalog® chez des sujets diabétiques de type 1” (Abstract CAD-19), presented by Dr. Grégory Meiffren, 2017, Société Francophone du Diabète (France)
“BioChaperone® Combo, une co-formulation liquide des insulines lispro et glargine, présente un contrôle glycémique amélioré par rapport à un premix d’insuline.” (Abstract CAD-19), presented by Dr. Claire Megret, 2017, Société Francophone du Diabète (France)
“BioChaperone® Combo (BC Combo) reduces post-prandial glucose in type 1 diabetes compared to conventional lispro mix 75/25 (LMx)” (Poster 836), presented by Dr. S. Bruce, 52nd European Association for the Study of Diabetes (EASD) Annual Meeting, 12–16 September 2016, Munich (Germany)
“A Pilot Bioequivalence (BE) Study of Ultra-Rapid Concentrated BioChaperone® Lispro (BCLIS) U200 to BCLIS U100”, (Abstract 2242-PUB), presented by Dr. Grit Anderson, 76th Scientific Sessions of the American Diabetes Association, 10-14 June 2016, New Orleans, LO (USA)
“Pharmacodynamic (PD) Profile of BioChaperone® Combo (BC Combo), a New Combination of Rapid-Acting and Long-Acting Insulin, in Subjects with Type 2 Diabetes Mellitus (T2DM)” (Poster 942), presented by Dr. Simon Bruce, 76th Scientific Sessions American Diabetes Association 11-13 June 2016, New Orleans, LO (USA)
“Ultra-Rapid BioChaperone® Insulin Lispro (BC LIS): Linear Dose-Response and Faster Absorption than Insulin Lispro (LIS)” (Poster 979), presented by Dr. Grit Anderson, 75th Scientific Sessions of the American Diabetes Association, 5-9 June 2015, Boston, MA (USA)
“Ultra-rapid BioChaperone® insulin Lispro (BC-LIS): linear dose-response and faster absorption than insulin Lispro (LIS)” (Poster 931), presented by Dr. Grit Anderson, 51st European Association for the Study of Diabetes (EASD) Annual Meeting, 15-18 September 2015, Stockholm (Sweden)
“The Ultra-Rapid BioChaperone® Insulin Lispro shows a Faster Onset of Action and Stronger Early Metabolic Effect than Native Insulin Lispro” (Poster 78-LB), presented by Dr. Grit Anderson, 74th Scientific Sessions of the American Diabetes Association, 13-17 June 2014, San Francisco, CA (USA)
“Pharmacokinetic (PK) and Pharmacodynamic (PD) Characteristics of BioChaperone Combo (BC Combo), the First Fixed Combination of Glargine and Lispro, in Type 1 Diabetes”, (Poster 83-LB), presented by Dr. Ulrike Hövelmann, 74th Scientific Sessions American Diabetes Association 13-17 June 2014, San Francisco, CA, (USA)
“The ultra-rapid BioChaperone® insulin lispro shows a faster onset of action and stronger early metabolic effect than insulin lispro alone” (Poster 934), presented by Dr. Grit Anderson, 50th European Association for the Study of Diabetes (EASD) Annual Meeting, 15–19 September 2014, Vienna (Austria)
“Pharmacokinetic (PK) and pharmacodynamic (PD) properties of BioChaperone® Combo (BC Combo), the first fixed combination of glargine and lispro, in type 1 diabetes (T1DM)” (Poster 932), presented by Dr. Ulrike Hövelmann, 50th European Association for the Study of Diabetes (EASD) Annual Meeting, 15–19 September 2014, Vienna (Austria)